

18 July 2025

**Solvonis Therapeutics plc**  
("Solvonis" or the "Company")

**Exercise of warrants**

Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders, announces that the Company has received a notice to exercise warrants over 20,000,000 new ordinary shares of £0.001 each in the Company (the "Warrant Shares") at an exercise price of £0.001 per Warrant Share, raising £20,000 of new funds for the Company.

**Admission and Total Voting Rights**

Application will be made for the Warrant Shares to be admitted to trading on the Main Market of the London Stock Exchange and to listing in the FCA's Official List Equity Shares (transition) category ("Admission"). It is expected that Admission will become effective at 8.00 a.m. on or around 24 July 2025.

Following Admission, the Company's issued ordinary share capital will comprise 6,262,104,024 ordinary shares of £0.001 each. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

**Enquiries:**

**Solvonis Therapeutics plc**  
Anthony Tennyson, CEO & Executive Director  
anthony@solvonis.com

**Allenby Capital Limited** (Financial Adviser and Joint Broker)  
Nick Naylor / Nick Athanas / Ashur Joseph (Corporate Finance)  
Guy McDougall (Sales & Corporate Broking)  
+44 (0) 20 3328 5656

**Singer Capital Markets** (Joint Broker)  
Phil Davies  
+44 (0) 20 7496 3000

**About Solvonis Therapeutics plc**

Solvonis Therapeutics plc (LSE: SVNS) is a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders. Headquartered in London and listed on the main market of the London Stock Exchange, Solvonis is advancing a differentiated pipeline of repurposed and novel compounds targeting high-burden neuropsychiatric conditions with significant unmet need.

The Company's lead programmes address Alcohol Use Disorder ("AUD") and Post-Traumatic Stress Disorder ("PTSD"), conditions which the Company estimates affect over 80 million people across the UK, US, and EU4. Its lead asset, SVN-001, is currently in Phase 3 for severe AUD in the UK and EU. SVN-002 is preparing for a Phase 2b trial in the US targeting moderate to severe AUD. Solvonis also has a preclinical PTSD programme leveraging novel serotonin-dopamine modulators designed to enhance pro-social behaviour and long-term outcomes.

In addition, Solvonis is advancing an AI-supported discovery programme built on a proprietary CNS compound library, with initial focus on depression and stimulant use disorders. This initiative expands the Company's R&D pipeline into earlier-stage innovation while maintaining strategic focus on comorbid and underserved neuropsychiatric conditions.

With a capital-efficient model, dual development strategy, and near-term partnering opportunities, Solvonis is positioned to generate value through innovation in neuropsychiatry.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

IOERPMMTMTMBBBA